NEW YORK (GenomeWeb News) – Abbott said today that it has completed the separation of its research-based pharmaceutical business, which has been spun out into a publicly traded entity called AbbVie.

Abbott announced its plans to split the company into two separate, publicly-traded companies — one focused on diversified medical products and the other on research-based pharmaceuticals — in October 2011.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.